In its Q3 2026 investor letter, White Brook Capital highlighted Codexis (NASDAQ:CDXS), which makes enzymes used to manufacture siRNA-based medicines, and said the stock holds call options with favorable payouts. On October 21, 2026, the stock closed at $1.29 with a market capitalization of $141.26 million, down 20.86% year to date and trading within a 52-week range of $0.96 to $2.98. However, 2026 has been marked by delays: three CDMO partners, Bachem, Nitto Denko Avecia and Axolabs, were signed early in the year, but only one has completed its technology evaluation, and long-term contract negotiations are still ongoing. Permitting delays have also hit its GMP-standard standalone facility, which is now scheduled to start production at year-end 2027, and the target for half-kilogram siRNA batches has moved to the end of this year or early next year.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Temporary Delays in siRNA Manufacturing Mask Codexis’ (CDXS) High-Option Value
Read the original on Yahoo Finance ↗
Keywords
CDXShealthcarepharmaceuticalssiRNA
Open a keyword to see other news on the same topic.
Related news
- New bipartisan bill aims to speed up clinical trials for rare disease treatments
Bipartisan Reps. Jake Auchincloss (D) and Morgan Griffith (R) introduced the "Faster Clinical Trials Act" to speed up studies of rare disease treatments, one week after the FDA unveiled a new initiative for these drugs. The bill would create a network of reusable clinical trial sites and a "Center for Clinical Trial Innovation" at the FDA, with up to $75 million in annual funding over five years. Its goal is to cut trial costs and enrollment time by at least 30%, and to let patients receive experimental drugs at their regular doctor's office, with progress tracked through Zoom, electronic health records or wearables. Griffith said this would also help patients who live hours away from medical centers.
- 7 healthcare stocks that stand out as investors pay up for the sector
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Changes to This $100 Billion Federal Drug Program Could Make Banks the Hidden Beneficiaries
A proposed overhaul of the $100 billion federal 340B drug-discount program would shift some discounts to rebates starting January 1, 2027, so hospitals must pay upfront and wait for reimbursement. In an illustrative example, an extra $10 million balance at 6% annual interest would cost about $50,000 per month, which could increase demand for credit lines from banks that already serve hospitals. The American Hospital Association estimates administrative costs could exceed $1 billion per year, compared with HRSA's $537 million estimate for submitting claims. The article notes the incremental lending demand is unquantified, and the program faces a lawsuit filed on October 9 after an earlier rebate pilot was blocked in December 2025. Banks would benefit only if added interest exceeds funding costs and credit losses.
- Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
- Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Alnylam shares have fallen more than 40% year to date, even though the company is now solidly profitable, with Q2 2026 GAAP net income of $164.5 million and revenue up 67% to $1.29 billion. The author attributes much of the selloff to two concerns: Alnylam cut its 2026 revenue guidance for Amvuttra and Onpattra to $4.2–4.5 billion from $4.4–4.7 billion as demand normalized after an initial surge of patients switching to Amvuttra, and disappointing Phase 3 results for Wainua in ATTR-CM raised worries about Alnylam's nucresiran. The author argues both concerns are overstated, since the two drugs use different mechanisms and Amvuttra sales continue to grow robustly. Of the 23 analysts who rated the stock over the past three months, 19 recommended buying, and the average 12-month price target implies 54% upside.
Related markets
Latest news
- SpaceX Just Crushed Wall Street's Q3 Targets -- but a Potential Tesla Merger Is Even Bigger News
SpaceX reported third-quarter adjusted EPS of $0.45 on sales of $14.58 billion, far above analyst averages of $0.13 and $12.72 billion. Revenue rose 161% year over year and net income swung to $4.4 billion from a $1.1 billion loss a year earlier; Starlink sales grew 69% to $5.25 billion, while the superintelligence segment rose about 830% to $7.56 billion. The company guided first-quarter 2027 sales to $33–37 billion, and Musk said he expects annual recurring revenue of $500 billion–$1 trillion by the end of next year. On the call, Musk said special committees had been formed to explore a merger with Tesla, that he could not take part due to conflicts, and that merging was a good idea, though shareholder approval equal to 50% of total shares would be a significant hurdle.
- Chip stocks break a bear trap after a $2.6 trillion rout — here are the levels bulls need to hold
The PHLX Semiconductor Index (^SOX) is down about 3% after dipping to 11,000, a support level that has rescued chip stocks twice since September, so the bear-trap rebound only holds if that floor does. Since Oct. 6, all 60 stocks in Yahoo Finance's chip basket have fallen, erasing about $2.7 trillion in market value; Lam Research and Applied Materials are each down nearly 30%, AMD nearly 20%, and Nvidia 9%. Lam fell despite record revenue because it said supply limits would cap its outlook and China sales would be “meaningfully down” in December. The Nasdaq 100 is down about 6% over the same period. The article flags 10,450–10,550 as the zone to watch if 11,000 breaks, and 12,600–12,700 as the level bulls must reclaim, while semiconductor ETFs saw record flows over the past week.
- A New Mexico Judge Just Hit Meta With a $25 Billion Penalty
On October 21, 2026, a New Mexico judge ordered Meta to pay the state $25 billion over misleading Facebook users about privacy in the Cambridge Analytica case, far above the FTC's $5 billion fine in 2019. Jurors found 26 of 29 statements misleading, and counting each statement per user or resident who saw it produced more than 43 million violations, with state law allowing up to $5,000 each; all the money goes to New Mexico schools. The judge said the conduct went to the heart of Facebook's core business and found that senior leaders, including Zuckerberg and Sandberg, misrepresented its privacy practices. Meta is appealing, has paid nothing, and interest keeps accruing, while the penalty equals about 2.5 times its $9.86 billion third-quarter net income.
- Elon Musk says Tesla's Optimus robot needs to learn like a toddler
Elon Musk said on Tesla’s earnings call that Optimus humanoid robots must learn through self-play at scale, since Tesla lacks the vast car fleet that supplies training data, likening this to how a toddler learns to navigate the world by playing. Tesla cut its 2026 capex outlook to about $20 billion from $25 billion as it prioritizes usable humanoids. Optimus V3 production began at Fremont in the summer after Model S and Model X output ended there, with about 1,000 Gen 3 units already operating on the production floor. William Blair analyst Jed Dorsheimer said Musk pushed the timeline for a 1 million-unit weekly run-rate to over a year, with first applications in dangerous industrial settings by the end of 2027.
- Meta's new stock sale sends one signal: AI demand isn't slowing down
Brian Sozzi of Yahoo Finance sees Meta's new non-voting share class as a positive signal. CFO Susan Li said the class can be used for capital raising, employee pay and acquisitions while preserving the voting power of existing Class A and B shareholders. Sozzi expects Zuckerberg to remain CEO for at least 15 more years, and says raising capital through stock may be cheaper than borrowing, since debt costs could rise for borrowers such as CoreWeave. He also reads the sale as a sign that AI demand is not slowing, pointing to better ad placement and monetization that helped the quarter's results.
- Elon Musk: SpaceX Revenue Could Hit “Somewhere Between $500 Billion and a Trillion” by 2027
On the earnings call, Elon Musk said SpaceX’s annual recurring revenue could reach between $500 billion and a trillion by the end of 2027, a goal that requires building compute faster than almost any company has tried. SpaceX posted its first quarterly profit of $4.4 billion in the latest quarter, versus a $1.1 billion loss a year earlier, with revenue up more than 160% to $14.6 billion; capex of $19.6 billion could reach $40 billion next quarter. Management says new compute installations pay back in under a year if prices hold, but the target of 13 GW by end-2027, up from 1.7 GW, depends on power, cooling, and NVIDIA’s Vera Rubin systems arriving on time. Shares rose 7.79% to $159.31, and a Tesla combination would need approval from 50% of Tesla’s outstanding shares, a hard bar given many holders never vote.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.